Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

2.940 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis ↗

April 07, 2022

Via Benzinga

Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study ↗

March 18, 2022

Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting.

Via Benzinga

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

March 18, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 08, 2022

Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a...

Via Benzinga

Seres Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Seres Therapeutics (NASDAQ:MCRB) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Earnings Preview: Seres Therapeutics ↗

February 28, 2022

Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit

February 22, 2022

From Seres Therapeutics

Via Business Wire

Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022

February 22, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

February 08, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022

January 24, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection ↗

January 20, 2022

Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (...

Via Benzinga

New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection

January 19, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)

January 19, 2022

Via AB Newswire

Topics Bonds Stocks

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Seres Therapeutics, Inc.

Via Business Wire

Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study ↗

December 16, 2021

Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate...

Via Benzinga

Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

December 16, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Jim Cramer Shares His Thoughts On Novavax, ViacomCBS And More ↗

December 06, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Seres Therapeutics, Inc. (NASDAQ:

Via Benzinga

52 Biggest Movers From Yesterday ↗

December 01, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...

Via Benzinga

Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday ↗

November 30, 2021

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

Via The Motley Fool

Topics Stocks

35 Stocks Moving In Tuesday's Mid-Day Session ↗

November 30, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...

Via Benzinga

Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)

November 30, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

November 24, 2021

From Seres Therapeutics, Inc.

Via Business Wire

Looking Into Seres Therapeutics's Return On Capital Employed ↗

November 11, 2021

According to Benzinga Pro, during Q3, Seres Therapeutics (NASDAQ:MCRB) earned $68.41 million, a 242.09% increase from the preceding quarter. Seres Therapeutics also posted a total...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; PubMatic Shares Gain After Q3 Results ↗

November 10, 2021

Toward the end of trading Wednesday, the Dow traded down 0.67% to 36,075.12 while the NASDAQ fell 1.90% to 15,585.20. The S&P also fell, dropping 0.99% to 4,638.64. The U.S....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 10, 2021

Gainers Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 31.29% to $9.02 during Wednesday's regular session. Trading volume for this security as of 12:30 EST...

Via Benzinga

76 Biggest Movers From Yesterday ↗

November 11, 2021

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...

Via Benzinga

Topics Initial Public Offering

Mid-Morning Market Update: Markets Edge Lower; US Inflation Rate Increases To 6.2% ↗

November 10, 2021

Following the market opening Wednesday, the Dow traded down 0.07% to 36,293.80 while the NASDAQ fell 0.23% to 15,850.04. The S&P also fell, dropping 0.05% to 4,682.75. The U.S...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 10, 2021

Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6...

Via Benzinga

Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 10, 2021

From Seres Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.